Trial Profile
A multicenter, prospective study evaluating the impact of JAKi on MGUS when initiated for an active rheumatic disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2022
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary) ; Tofacitinib (Primary) ; Upadacitinib (Primary)
- Indications Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions
- Acronyms Jakpic
- 29 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism